摘要
慢性丙型肝炎(CHC)病毒感染和相关肝病仍然具有挑战性,世界各地的疾病负担仍然很大。慢性感染患者的总体治疗率“非常差”,在现实的临床环境中,聚乙二醇化干扰素(PEG-IFN)和利巴韦林(RBV)双重治疗的完成情况并不理想。第一代、第二代和下一代直接作用抗病毒药物(DAAS)的批准是丙型肝炎病毒(HCV)治疗方法在治疗CHC感染者方面的重大突破。这种固定剂量组合(FDC)或RBV的治疗方案已经证明了它们对不同HCV基因型的临床疗效,并且难以治疗特殊人群。我们继续看到新的泛基因型抗-HCV方案的发展,其持续病毒学应答(SVR;第12周或治疗结束时检测不到的病毒载量)非常高,对药物抵抗的高屏障,不良事件的发生率较低,与一些老的基于RBV的三重DAA疗法相比,药物相互作用更少。口服无干扰素DAAS似乎是治疗丙型肝炎的非常成功的战略治疗方法,并促使卫生政策制定者制定治疗优先顺序和政策,以降低丙型肝炎相关发病率和死亡率。本文全面综述了无干扰素抗-HCV方案,这些方案在一定程度上改变了丙型肝炎的治疗模式,并带来了一些额外的好处,以激励我们在不久的将来努力实现消除HCV的全球目标。
关键词: 无干扰素抗病毒药物、蛋白酶抑制剂、NS5a抑制剂、NS5b抑制剂、泛基因型治疗方案、DAA失败、HCV治疗。
Current Molecular Medicine
Title:All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C
Volume: 18 Issue: 7
关键词: 无干扰素抗病毒药物、蛋白酶抑制剂、NS5a抑制剂、NS5b抑制剂、泛基因型治疗方案、DAA失败、HCV治疗。
摘要: Chronic hepatitis C (CHC) virus infection and associated hepatic diseases are still challenging, and the disease burden remains significant around the world. Overall treatment rates for the chronically infected patients have been “dismally poor” and that treatment completion of dual-therapy— pegylated interferon (PEG-IFN) and ribavirin (RBV) is suboptimal in the real-world clinical settings. The approval of first, second and next-generation direct-acting antivirals (DAAs) represents a major breakthrough in hepatitis C virus (HCV) therapeutics to treat CHC infected individuals. Such therapeutic regimens in a fixed dose combination (FDC) or along with RBV have proven their clinical efficacy against different HCV genotypes, and harder-to-treat special populations. We continue to see the development of novel pan-genotypic anti-HCV regimens with very high sustained virologic response (SVR; undetectable viral load at week 12 or at the end of therapy) rates, high barrier to drug resistance, low frequency of adverse events, and fewer drug-drug interactions as compared to some older RBV based triple DAA therapies. Oral interferon-free DAAs seem highly successful strategic treatment approaches against hepatitis C and impulse health policy makers to establish the treatment priorties and policies to reduce the rate of hepatitis C-related morbidity and mortality. This review article comprehensively overviews interferon-free anti-HCV regimens, which have totally shifted the treatment paradigms for hepatitis C with some additional benefits to galvanize our efforts to achieve the global goal of HCV elimination in near future.
Export Options
About this article
Cite this article as:
All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C, Current Molecular Medicine 2018; 18 (7) . https://dx.doi.org/10.2174/1566524019666190104110439
DOI https://dx.doi.org/10.2174/1566524019666190104110439 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Management of Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Current Immunology Reviews (Discontinued) Dimethyloxallyl Glycine-Incorporated Borosilicate Bioactive Glass Scaffolds for Improving Angiogenesis and Osteogenesis in Critical-Sized Calvarial Defects
Current Drug Delivery Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials Anticancer Drugs Discovery and Development from Marine Organisms
Current Topics in Medicinal Chemistry The Role of Histone Demethylase GASC1 in Cancer and its Therapeutic Potential
Current Cancer Therapy Reviews Deregulation of HOX B13 Expression in Urinary Bladder Cancer Progression
Current Medicinal Chemistry Radiological Screening Programs for Women at High Risk of Developing Breast Cancer
Current Women`s Health Reviews Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?
Current Vascular Pharmacology Subject Index To Volume 8
Current Pharmaceutical Design Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry New Player on An Old Field; the Keap1/Nrf2 Pathway as a Target for Treatment of Type 2 Diabetes and Metabolic Syndrome
Current Diabetes Reviews Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals Ferroptosis: A Trusted Ally in Combating Drug Resistance in Cancer
Current Medicinal Chemistry Classical to Current Approach for Treatment of Psoriasis: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Viral Origins of Human Cancer
Current Medicinal Chemistry The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry